The Accountability Problem of the National Institute for Health and Clinical Excellence
Medicine and Law: The World Association for Medical Law 2008 March; 27(1): 83-93
The paper is a reflection on some of the ethical issues relating to decisions on the availability of new drugs made by the British National Institute for Health and Clinical Excellence (NICE). It outlines the way in which the Institute and its advisory committees make decisions on the funding of new treatments by the National Health Service and discusses the proposition that the organisational structures and methods of the Institute give rise to an accountability problem. It is suggested that NICE should simplify the way decisions are made, take proactive steps to better inform the public about the advantages and limitations of its approach, and provide a clearer distinction between the Institute itself and the appeal panels, which consider objections to its decisions.
Showing items related by title, author, creator and subject.
The Use of Cost-Effectiveness by the National Institute for Health and Clinical Excellence (NICE): No(t Yet An) Exemplar of a Deliberative Process Schlander, M. (2008-07)Democratic societies find it difficult to reach consensus concerning principles for healthcare distribution in the face of resource constraints. At the same time the need for legitimacy of allocation decisions has been ...